These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 688611)

  • 21. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
    Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
    Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of tamoxifen and N-desmethyltamoxifen in human plasma by high-performance liquid chromatography, photochemical reaction and fluorescence detection, and its application to biopharmaceutic investigations.
    Nieder M; Jaeger H
    J Chromatogr; 1987 Jan; 413():207-17. PubMed ID: 3558670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spectrofluorimetric determination of 2-chloro-2'-deoxyadenosine (cladribine) in human plasma by photochemical reaction and chloroacetaldehyde derivatization.
    Gajewska M; Pawiński T; Dzierzgowska-Szmidt A; Kazimierczuk Z
    Pharmazie; 1995 Jul; 50(7):459-60. PubMed ID: 7675888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative measurement of 4-hydroxy tamoxifen in human plasma and mammary tumours by combined gas chromatography/negative chemical ionization mass spectrometry.
    Girault J; Istin B; Fourtillan JB
    Biol Mass Spectrom; 1993 Jul; 22(7):395-402. PubMed ID: 8357855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Lim YC; Desta Z; Flockhart DA; Skaar TC
    Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
    Dahmane E; Boccard J; Csajka C; Rudaz S; Décosterd L; Genin E; Duretz B; Bromirski M; Zaman K; Testa B; Rochat B
    Anal Bioanal Chem; 2014 Apr; 406(11):2627-40. PubMed ID: 24633563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of bioavailability in man of tamoxifen after oral and rectal administration.
    Tukker JJ; Blankenstein MA; Nortier JW
    J Pharm Pharmacol; 1986 Dec; 38(12):888-92. PubMed ID: 2880961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selected reaction monitoring LC-MS determination of idoxifene and its pyrrolidinone metabolite in human plasma using robotic high-throughput, sequential sample injection.
    Onorato JM; Henion JD; Lefebvre PM; Kiplinger JP
    Anal Chem; 2001 Jan; 73(1):119-25. PubMed ID: 11195494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrokinetic supercharging in nonaqueous capillary electrophoresis for online preconcentration and determination of tamoxifen and its metabolites in human plasma.
    Thang LY; Breadmore MC; See HH
    J Chromatogr A; 2016 Aug; 1461():185-91. PubMed ID: 27485148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of panomifene in human plasma by high-performance liquid chromatography.
    Erdélyi-Tóth V; Pap E; Kralovánszky J; Bojti E; Klebovich I
    J Chromatogr A; 1994 May; 668(2):419-25. PubMed ID: 8032491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
    Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
    Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma.
    Daniel P; Gaskell SJ; Bishop H; Campbell C; Nicholson RI
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1183-9. PubMed ID: 7199465
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
    Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
    Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Concentration of Tamoxifen and Its Metabolites in a Neonate and Mother Receiving Tamoxifen: A Case Report of a Pregnant Woman.
    Konishi K; Miyazono Y; Doki K; Kido T; Hitaka D; Kanai Y; Takada H; Homma M
    Ther Drug Monit; 2019 Jun; 41(3):405-406. PubMed ID: 31083042
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of tamoxifen and its metabolites in synthetic gastric fluid digests and urine samples using high-performance liquid chromatography with electrospray mass spectrometry.
    Li XF; Carter S; Dovichi NJ; Zhao JY; Kovarik P; Sakuma T
    J Chromatogr A; 2001 Apr; 914(1-2):5-12. PubMed ID: 11358230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive high-performance liquid chromatographic determination of EM523, a new erythromycin derivative, in human plasma and urine with ultraviolet detection using column switching.
    Yamashita K; Motohashi M; Yashiki T
    J Chromatogr; 1993 Jun; 616(1):144-50. PubMed ID: 8376485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy.
    Bain RR; Jordan VC
    Biochem Pharmacol; 1983 Jan; 32(2):373-5. PubMed ID: 6870963
    [No Abstract]   [Full Text] [Related]  

  • 40. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
    Henderson SL; Teft WA; Kim RB
    BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.